Revolution Medicines (RVMD) Stock

When underwriters fully use their option, they generate a total of $862.5 million in gross earnings.

Revolution Medicines' shares have risen by more than 30% since April, thanks to encouraging clinical results for its main drug, RMC-6236, which targets cancers with RAS mutations. RMC-6236 demonstrates strong effectiveness in pancreatic cancer and may also be used for lung and colorectal cancers, making it a possible new treatment standard. Although the stock recently fell after a $600 million public offering, the company's strong cash reserves and promising drug development pipeline suggest good long-term prospects.

Revolution Medicines, Inc., a company focused on developing targeted cancer therapies, has announced the pricing of over 14 million shares of its common stock at $46.00 each. They are also offering pre-funded warrants for nearly 2.2 million shares at a price of $45.9999 each. The total expected proceeds from this offering are around $750 million, and the deal is set to close on December 5, 2024, pending standard conditions.

Revolution Medicines, Inc., a company focused on developing targeted cancer therapies, has announced a public offering to sell up to $600 million in common stock. The company will offer all the shares itself and plans to give underwriters a 30-day option to buy an extra $90 million in shares. The completion of this offering depends on market conditions, and there is no guarantee regarding its timing or final details.

Revolution Medicines, Inc., a company focused on developing targeted treatments for RAS-addicted cancers, has announced that it will hold a webcast for investors. This event will share the latest clinical updates on its RAS(ON) inhibitor portfolio. The announcement was made on November 27, 2024, from Redwood City, California.

The initial clinical findings for RMC-9805, a selective inhibitor for the RAS(ON) G12D mutation, show promising tolerability and effectiveness against tumors in patients with pancreatic ductal adenocarcinoma (PDAC).

The results show positive outcomes for progression-free survival and overall survival, with safety findings matching earlier reports and no new safety concerns identified. An investor webcast is scheduled for Friday, October 25, at 12:00 p.m. Eastern Time (ET) in Redwood City, California.

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a company focused on developing targeted cancer treatments, has announced that the first patient has received treatment in the RASolute 302 study. This Phase 3 study is testing RMC-6236, a multi-selective inhibitor for RAS(ON), in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

Revolution Medicines, Inc. (NASDAQ:RVMD) will hold its Q2 2024 Earnings Conference Call on August 7, 2024, at 4:30 PM ET. The call will feature key company leaders, including Ryan Asay, Mark Goldsmith, and Jack Anders, among others. Various financial analysts from firms like TD Cowen, JPMorgan, and Goldman Sachs will also participate in the call.